Outcome and survival of asymptomatic PML in natalizumab-treated MS patients.

Dong-Si, Tuan; Richman, Sandra; Wattjes, Mike P; Wenten, Made; Gheuens, Sarah; Philip, Jeffrey; Datta, Shoibal; McIninch, James; Bozic, Carmen; Bloomgren, Gary; Richert, Nancy

Dong-Si, Tuan; Richman, Sandra; Wattjes, Mike P; Wenten, Made; Gheuens, Sarah; Philip, Jeffrey; Datta, Shoibal; McIninch, James; Bozic, Carmen; Bloomgren, Gary; Richert, Nancy.

Afiliação

Dong-Si T; Drug Safety and Risk Management, Biogen Idec Inc. Cambridge, Massachusetts.
Richman S; Drug Safety and Risk Management, Biogen Idec Inc. Cambridge, Massachusetts.
Wattjes MP; MS Center Amsterdam, Department of Radiology, Nuclear Medicine & PET Research, VU University Medical Center Amsterdam, The Netherlands.
Wenten M; Drug Safety and Risk Management, Biogen Idec Inc. Cambridge, Massachusetts.
Gheuens S; Drug Safety and Risk Management, Biogen Idec Inc. Cambridge, Massachusetts.
Philip J; Data Sciences, Biogen Idec Inc. Cambridge, Massachusetts.
Datta S; Data Sciences, Biogen Idec Inc. Cambridge, Massachusetts.
McIninch J; Data Sciences, Biogen Idec Inc. Cambridge, Massachusetts.
Bozic C; Drug Safety and Risk Management, Biogen Idec Inc. Cambridge, Massachusetts.
Bloomgren G; Drug Safety and Risk Management, Biogen Idec Inc. Cambridge, Massachusetts.
Richert N; Neurology Research and Development, Biogen Idec Inc. Cambridge, Massachusetts.

Ann Clin Transl Neurol ; 1(10): 755-64, 2014 Oct.

Article em En | MEDLINE | ID: mdl-25493267

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Ann Clin Transl Neurol Ano de publicação: 2014 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Ann Clin Transl Neurol Ano de publicação: 2014 Tipo de documento: Article